Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EG-70 |
Synonyms | |
Therapy Description |
EG-70 consists of a DNA vector engineered to express interleukin-12 (IL-12) and a retinoic acid-inducible gene I protein (RIG-I; DDX58) activator in a nanoparticle-based formulation, which leads to increased levels of IL-12, and potentially results in activation of an antitumor immune response (Urologic Oncology, 42, Supplement, 2024, S48). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EG-70 | EG 70|EG70|Detalimogene voraplasmid | EG-70 consists of a DNA vector engineered to express interleukin-12 (IL-12) and a retinoic acid-inducible gene I protein (RIG-I; DDX58) activator in a nanoparticle-based formulation, which leads to increased levels of IL-12, and potentially results in activation of an antitumor immune response (Urologic Oncology, 42, Supplement, 2024, S48). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04752722 | Phase Ib/II | EG-70 | EG-70 in NMIBC Patients Who Are BCG-Unresponsive and High-Risk NMIBC Patients Who Have Been Incompletely Treated With BCG or Are BCG-Naïve (LEGEND STUDY) | Recruiting | USA | CAN | 0 |